Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study

JAMA Internal Medicine

Volumn 173, Issue 9, 2013, Pages 743-752

  Johannesdottir, Sigrun A ^a   Horváth Puh́o, Erzseb́et ^a   Dekkers, Olaf M ^b   Cannegieter, Suzanne C ^b   Jørgensen, Jens Otto L ^a   Ehrenstein, Vera ^a   Vandenbroucke, Jan P ^b   Pedersen, Lars ^a   Srøensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; AZATHIOPRINE; BETAMETHASONE; CYCLOSPORIN; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

AGED; BETAMETHASONE; CASE-CONTROL STUDIES; DENMARK; DRUG PRESCRIPTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INCIDENCE; LOGISTIC MODELS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; ODDS RATIO; PREDNISOLONE; PREDNISONE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TRIAMCINOLONE; VENOUS THROMBOEMBOLISM;

EID: 84877737822     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.122     Document Type: Article

References (45)

1. Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363(9417):1295-1305. (Pubitemid 38496494)
2. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370-372.
3. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365(9465):1163- 1174. (Pubitemid 40417567)
4. pro.medicin.dk. Information on glucocorticoid package sizes and indications in Denmark [in Danish]. http://pro.medicin.dk/Laegemiddelgrupper/ Grupper/171030. Accessed May 30, 2012.
5. Danish Medicines Agency. Information on over-the-counter medicine and reimbursement criteria in Denmark. http://laegemiddelstyrelsen.dk/en/. Accessed May 30, 2012.
6. Squizzato A, Gerdes VE, Ageno W, Büller HR. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med. 2007;2(2):76-83.
7. van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483-2493.
8. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96(11):3525-3532.
9. Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94(8):2743-2750.
10. Calvo-Alén J, Toloza SM, Fernández M, et al LUMINA Study Group. Systemic lupus erythematosus in amultiethnic US cohort (LUMINA), XXV: smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005;52(7):2060-2068. (Pubitemid 40994330)
11. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007; 45(2):335-342.
12. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010; 375(9715):657-663.
13. Mukherjee AP, Toh BH, Chan GL, Lau KS, White JC. Vasculas complications in nephrotic syndrome: relationship to steroid therapy and accelerated thromboplastin generation. Br Med J. 1970;4(5730):273-276.
14. Russell MW, Taylor DC, Cummins G, Huse DM. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care. 2002;8(1)(suppl):S3-S9. (Pubitemid 34116303)
15. Stolz E, Klötzsch C, Schlachetzki F, Rahimi A. High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol. 2003;49(4):247-248. (Pubitemid 36566245)
16. Yale SH, Medlin SC, Liang H, Peters T, Glurich I, Mazza JJ. Risk assessment model for venothromboembolism in post-hospitalized patients. Int Angiol. 2005;24 (3):250-254. (Pubitemid 41582333)
17. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost. 2011;37(3):209-219.
18. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med . 2007;167(9):935-943. (Pubitemid 46762756)
19. Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011; 39(7)(suppl):22-25.
20. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012;4:303-313.
21. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7)(suppl):30-33.
22. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010;63(2):223-228.
23. Johannesdottir SA, Schmidt M, Horváth-Puhó E, Sørensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2012;10(5):815-821.
24. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993;22(6):1189-1192. (Pubitemid 24025700)
25. Sørensen GV, Cronin-Fenton DP, Sørensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21. doi:10.1186/bcr3106.
26. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sørensen HT. Acute infections and venous thromboembolism. J Intern Med . 2012;271(6):608-618.
27. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-249.
28. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21(1):41-46.
29. Schmidt M, Christiansen CF, Horváth-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011;9(7):1326-1333.
30. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
31. Greenland S. Estimation of exposure-specific rates from sparse case-control data. J Chronic Dis. 1987;40(12):1087-1094. (Pubitemid 17158140)
32. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453-1457. (Pubitemid 24351698)
33. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45 (5):419-425. (Pubitemid 28227341)
34. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012; 35(3):191-205.
35. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118(2):247-252. (Pubitemid 43833323)
36. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868-875.
37. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(1):CD002913. doi:10.1002/14651858.CD002913.pub2.
38. Baid SK, Nieman LK. Therapeutic doses of glucocorticoids: implications for oral medicine. Oral Dis. 2006;12(5):436-442. (Pubitemid 44252535)
39. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881- 1893. (Pubitemid 36645187)
40. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72(1):39-45. (Pubitemid 21921653)
41. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) . 1997;46(3):263-268. (Pubitemid 27174327)
42. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) . 1997;46 (3):255-261. (Pubitemid 27174326)
43. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as two sides of the spectrum. Blood. 2012;120(5):933-946.
44. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The National Patient Registry: evaluation of data quality [in Danish]. Ugeskr Laeger. 1995;157(26):3741-3745.
45. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83. doi:10.1186/1471-2288-11-83.